ATS PITB Assembly (@ats-pitb) — Bluesky Profile

1 week ago

❄️🗞️ The PITB Highlights Winter Newsletter is here! Get an inside look at what our members are excited about at #ATS2026, catch up on the latest articles, and check out the return of the Vaccine and Immunization Advisory Group 🫁

@atscommunity.bsky.social
@ats-rsf.bsky.social

2 0 0 0

3 weeks ago

Airway microbiome dysbiosis in severe pneumonia: metagenomic evidence of pathogen expansion and commensal depletion

Wang and colleagues used bronchoalveolar lavage to study the lung microbiome of severe and non-severe pneumonia in a multi-centre study from China. Here the authors discuss a depletion of oral commensals that is associated with more severe pneumonia in the lower airway. rdcu.be/e4JDT

0 0 0 0

1 month ago

Noncystic Fibrosis Bronchiectasis: From Foundation to Clinical Practice | Webinar - American College of Chest Physicians In this webinar, members of the CHEST Airways Disorders Network’s Bronchiectasis Section explore how alterations in mucus properties contribute to the development and progression of noncystic fibrosis...

Drs. Green, Devarajan, Swenson, Losier, and Gu discuss non-cystic #bronchiectasis emphasising the importance of mucus, from biochemical properties to clinical practice. A must view for those interested in #bronchiectasis research. #Chest #ATS

www.chestnet.org/guidelines-a...

0 0 0 0

1 month ago

Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial Mtb was the most common pathogen causing sepsis and bloodstream infection and was frequently missed by conventional rapid diagnostics. We also identified a high prevalence of non-mycobacterial pathoge...

Associated secondary analysis here: Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial - eClinicalMedicine www.thelancet.com/journals/ecl...

3 2 1 0

1 month ago

🔥🔥🔥 HOT OF THE PRESS!🔥🔥🔥
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial - The Lancet Infectious Diseases www.thelancet.com/journals/lan...

3 2 2 0

1 month ago

American Thoracic Society | Assembly Leadership Voting The American Thoracic Society is the world's leading medical society dedicated to accelerating the advancement of global respiratory health through…

🚨Don’t miss the deadline—vote now for your Assembly leaders!

site.thoracic.org/membership/a...

0 0 0 0

1 month ago

Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients: a comparative study - BMC Infectious Diseases BMC Infectious Diseases - This study aimed to evaluate the association between the use of Nirmatrelvir-ritonavir (NMVr) and the risk of intubation or in-hospital mortality among severe COVID-19...

This retrospective cohort study assessed nirmatrelvir–ritonavir (NMVr) effectiveness in severe COVID-19 using real-world data. 🦠🧫

Results showed NMVr therapy was associated with lower risks of intubation and in-hospital mortality.

link.springer.com/article/10.1...

0 0 0 0

1 month ago

Vitamin D Deficiency at Hospital Admission With Community-Acquired Pneumonia is Associated With Increased Risk of Mortality: A Prospective Cohort Study A deficient vitamin D status was linked to increased 90- and 180-day mortality in adults hospitalized with CAP, despite milder disease upon admission. No a

Hein et al. investigated the association between vitamin D status and mortality in patients hospitalized with CAP 💊🫁

Results suggested a higher risk of 90- and 180-day mortality among those with vitamin D deficiency.

academic.oup.com/ofid/article...

1 0 0 0

1 month ago

Bronchiectasis Education Center: Ask the Expert with Anne O’Donnell, MD

Join leading expert, Ashley Losier, MD, from Yale University, for an interactive “Ask the Expert” session on bronchiectasis at 1 p.m. ET on January 28, 2026.

Registration is required and is free – https://ow.ly/1Bcs50XWGES

0 2 0 5

1 month ago

🫁Sensitization to recombinant Aspergillus fumigatus (rAsp f) is a key trait in bronchiectasis.

This multicenter study across four countries links rAsp f allergen responses to severe exacerbations, especially in those with <3 events/year. #CHESTjournal

journal.chestnet.org/article/S001...

0 0 0 0

1 month ago

🧫 In this ENIRRI secondary analysis of 1,059 ICU patients with nosocomial respiratory infections, P. aeruginosa accounted for 14.5% of cases and was strongly associated with COPD GOLD D, autoimmune disease, chronic kidney disease, and early acute kidney injury. 🫁

buff.ly/HuqtpoR

0 0 0 0

2 months ago

🧪Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Ian Galbreath, MD!🔬 Dr. Galbreath's research has focused on early life viral infections 🦠 and development of asthma. 🧫 When he is not seeing patients, he is an avid runner! 🏃 🥼

1 0 1 0

2 months ago

mHealth Intervention for Smoking Cessation This cluster randomized trial assesses the effectiveness of a mobile health text-message intervention, compared with usual care, for achieving continuous tobacco abstinence at 6 months in people with ...

🫁Latest in implementation science, mHealth for TB + smokers: Cluster RCT in Pakistan (n=1080) found daily→monthly text messages tripled biochemically confirmed 6‑mo abstinence (41.7% vs 15.3%; RR≈3.0) without harming TB outcomes!📱
jamanetwork.com/journals/jam...

0 0 0 0

2 months ago

New in Nature Medicine: Modeling of 6.8M TB notifications from 111 LMICs shows that scaling up PCR-based diagnostics mainly reduces missed TB (false negatives), but has a much smaller impact on false-positive diagnoses driven by clinical judgment alone. t.co/RheMwTphqK

0 0 0 0

2 months ago

High-Dose Influenza Vaccine to Reduce Hospitalizations | NEJM

✨ Recently published: Among adults aged 65–79 in the GALFLU trial (n=103,169), the high-dose inactivated influenza vaccine appeared to be associated with fewer hospitalizations for influenza or PNA compared with the standard dose. #NEJM

www.nejm.org/do/10.1056/N...

0 0 0 0

3 months ago

Upper-Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study | American Journal of Respiratory and Critical Care Medicine Rationale: Infection is a key disease driver in bronchiectasis, and the upper-airway microbiome has been known to shape the lower-airway microbiome.

✨ Recently published in AJRCCM: Data from the EMBARC-BRIDGE study show a key link between the upper-airway microbiome and clinical outcomes in patients with bronchiectasis.

www.atsjournals.org/doi/epdf/10....

1 0 0 0

3 months ago

🧪Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Pramod Bhattarai!🔬 Dr. Bhattarai serves rural and underserved communities and his research focuses on health disparities, particularly in people living with HIV. 🧫 When out of the clinic, he enjoys coin collecting 🪙 and hiking 🥾!

1 1 0 0

3 months ago

A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia | NEJM Adjunctive glucocorticoids may reduce mortality among patients with severe community-acquired pneumonia (CAP) in well-resourced settings. Whether these drugs are beneficial in low-resource settings...

In the SONIA trial, adjunct low-dose glucocorticoid use in patients hospitalized with CAP in a low-resource setting was associated with lower 30-day all-cause mortality compared with standard care. #NEJM

www.nejm.org/doi/full/10....

1 0 0 0

3 months ago

COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults in France This cohort study uses the data from all adults aged 18 to 59 years living in France on November 1, 2021, to evaluate whether there is an association of receipt of an mRNA COVID-19 vaccine with long-t...

A cohort study of 28 million individuals aged 18–59 found no increased risk of 4-year all-cause mortality among those vaccinated against COVID-19. #JAMA

jamanetwork.com/journals/jam...

1 0 0 0

3 months ago

Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome : A Systematic Review and Meta-analysis - PubMed None. (PROSPERO: CRD42024536301).

Soulmate et al.’s meta-analysis showed, with moderate certainty of evidence, that adjunctive low-dose, short-course corticosteroids probably reduce short-term mortality in both severe PNA and ARDS.

pubmed.ncbi.nlm.nih.gov/41325621/

0 0 1 0

3 months ago

📢📢📢Less than a week left! Learn the latest on HIV-associated lung disease in the upcoming 🌲PINE Webinar on #worldaidsday December 1st! @idsainfo.bsky.social @atscommunity.bsky.social @btsrespiratory.bsky.social @theunion.org

Sign up here: thoracic.zoom.us/webinar/regi...

1 0 0 0

3 months ago

Selective Decontamination of the Digestive Tract during Ventilation in the ICU | NEJM Whether selective decontamination of the digestive tract (SDD) reduces mortality among patients undergoing mechanical ventilation and whether it adversely affects microbial ecology in the intensive...

Among mechanically ventilated patients, selective digestive decontamination did not reduce in-hospital mortality compared with standard care. #NEJM #PITB #SuDDICU

www.nejm.org/doi/full/10....

0 0 0 0

3 months ago

Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia publications.ersnet.org/content/erj/...

3 1 1 0

3 months ago

European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis BackgroundBronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.MethodsA European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist, and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction, and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of 8 PICO (Patient, Intervention, Comparator, Outcomes) questions and 3 narrative questions were developed.RecommendationsThe Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations, and managing the deteriorating patient.ConclusionThe ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.Scope and objectivesThe European Respiratory Society (ERS) guidelines for the management of bronchiectasis in adults provide evidence-based recommendations for the care of people with clinically significant bronchiectasis, defined by the presence of permanent dilatation of the bronchi evident on chest CT scan, along with characteristic clinical symptoms. [1] These guidelines are intended for all healthcare professionals involved in the care of adults with bronchiectasis, as well as for policymakers, regulatory authorities, and pharmaceutical companies. Bronchiectasis is a complex and heterogeneous disease; therefore, no guideline can be entirely comprehensive or replace clinical judgement. All guideline recommendations must be interpreted within the specific clinical context in which they are applied. Separate ERS guidelines for the management of bronchiectasis in children exist [2]. Bronchiectasis due to cystic fibrosis (CF) has a distinct evidence base; therefore, guidance for the management of CF is provided elsewhere. [3] Some bronchiectasis-associated conditions also have distinct guidelines for investigation and management, such as primary ciliary dyskinesia (PCD) [4], allergic bronchopulmonary aspergillosis (ABPA) [5] and non-tuberculous mycobacterial (NTM) pulmonary disease [6]. While the present guidelines apply for these conditions, they should be interpreted in conjunction with the relevant syndrome-specific recommendations.

🚨 New 2025 ERS guidelines for the management of adult bronchiectasis! Takeaway:

Recommend to offer long-term macrolides to patients at high risk of exacerbations. High-risk features include P. aeruginosa infection, COPD, PCD, RA, and sputum purulence.

doi.org/10.1183/1399...

0 0 0 0

4 months ago

European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis BackgroundBronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.MethodsA European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist, and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction, and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of 8 PICO (Patient, Intervention, Comparator, Outcomes) questions and 3 narrative questions were developed.RecommendationsThe Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations, and managing the deteriorating patient.ConclusionThe ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.Scope and objectivesThe European Respiratory Society (ERS) guidelines for the management of bronchiectasis in adults provide evidence-based recommendations for the care of people with clinically significant bronchiectasis, defined by the presence of permanent dilatation of the bronchi evident on chest CT scan, along with characteristic clinical symptoms. [1] These guidelines are intended for all healthcare professionals involved in the care of adults with bronchiectasis, as well as for policymakers, regulatory authorities, and pharmaceutical companies. Bronchiectasis is a complex and heterogeneous disease; therefore, no guideline can be entirely comprehensive or replace clinical judgement. All guideline recommendations must be interpreted within the specific clinical context in which they are applied. Separate ERS guidelines for the management of bronchiectasis in children exist [2]. Bronchiectasis due to cystic fibrosis (CF) has a distinct evidence base; therefore, guidance for the management of CF is provided elsewhere. [3] Some bronchiectasis-associated conditions also have distinct guidelines for investigation and management, such as primary ciliary dyskinesia (PCD) [4], allergic bronchopulmonary aspergillosis (ABPA) [5] and non-tuberculous mycobacterial (NTM) pulmonary disease [6]. While the present guidelines apply for these conditions, they should be interpreted in conjunction with the relevant syndrome-specific recommendations.

🚨New 2025 ERS guidelines for the management of adult bronchiectasis! Key takeaway:

Recommend not offering long-term ICS to patients with bronchiectasis who do not have coexisting asthma or COPD.

doi.org/10.1183/1399...

0 0 0 0

4 months ago

Welcome! You are invited to join a webinar: Pulmonary Infections Network of Experts: A Case of HIV-Associated Lung Disease. After registering, you will receive a confirmation email about joining the w... Josalyn Cho, MD, University of Iowa, and Neelima Navuluri, MD, MPH, Duke University, will be discussing a case of HIV-associated lung disease to mark World AIDS Day, presented by Jonah Kreniske, MD, o...

🔥Mark your calendars!🔥
@ATS_PITB
is hosting a🌲PINE🌲Webinar on HIV-associated lung disease 🫁 Case-based discussion, with🌍global experts!
📅 Monday, December 1st 3PM ET
🗒️Register Here: thoracic.zoom.us/webinar/regi...
#TB @ATS_Assemblies
@IDSAInfo
@TheUnion_TBLH
@BTSrespiratory

0 0 0 1

4 months ago

European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis BackgroundBronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.MethodsA European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist, and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction, and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of 8 PICO (Patient, Intervention, Comparator, Outcomes) questions and 3 narrative questions were developed.RecommendationsThe Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations, and managing the deteriorating patient.ConclusionThe ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.Scope and objectivesThe European Respiratory Society (ERS) guidelines for the management of bronchiectasis in adults provide evidence-based recommendations for the care of people with clinically significant bronchiectasis, defined by the presence of permanent dilatation of the bronchi evident on chest CT scan, along with characteristic clinical symptoms. [1] These guidelines are intended for all healthcare professionals involved in the care of adults with bronchiectasis, as well as for policymakers, regulatory authorities, and pharmaceutical companies. Bronchiectasis is a complex and heterogeneous disease; therefore, no guideline can be entirely comprehensive or replace clinical judgement. All guideline recommendations must be interpreted within the specific clinical context in which they are applied. Separate ERS guidelines for the management of bronchiectasis in children exist [2]. Bronchiectasis due to cystic fibrosis (CF) has a distinct evidence base; therefore, guidance for the management of CF is provided elsewhere. [3] Some bronchiectasis-associated conditions also have distinct guidelines for investigation and management, such as primary ciliary dyskinesia (PCD) [4], allergic bronchopulmonary aspergillosis (ABPA) [5] and non-tuberculous mycobacterial (NTM) pulmonary disease [6]. While the present guidelines apply for these conditions, they should be interpreted in conjunction with the relevant syndrome-specific recommendations.

🚨New 2025 ERS guidelines for the management of adult bronchiectasis! Key update:

Recommend offering long‑term inhaled antibiotics to patients at high risk of exacerbations and with chronic Pseudomonas aeruginosa infection despite standard care.

publications.ersnet.org/content/erj/...

0 0 0 0

4 months ago

Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond | American Journal of Respiratory and Critical Care Medicine

💫In this randomized, phase 2 clinical trial, telacebec demonstrated antimycobacterial activity over 14 days in patients with smear-positive pulmonary TB. #AJRCCM

doi.org/10.1164/rccm...

0 0 0 0

4 months ago

⏰Only a few hours left to submit abstracts and case reports for #ATS2026! ⏰

The ATS is accepting scientific abstracts and case reports on all aspects of respiratory disease, critical care, and sleep medicine for ATS 2026.

Deadline is 5 p.m. ET, Nov. 5, 2025: conference.thoracic.org/program/call...

3 3 0 0

4 months ago

New #IDSAGuidelines! IDSA has released updated evidence-based recommendations on administering age-appropriate Influenza and RSV vaccinations in populations with compromised immunity. https://www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/

8 5 0 6